newsfilter
← Earnings
Earnings Releases·

TG Therapeutics — Third Quarter 2026 Earnings Summary

  • Total global revenue reached $260 million in Q3 2026, up from $161.7 million in Q3 2025, driven by a 52% year-over-year increase in BRIUMVI U.S. net product revenue to $232.6 million.
  • Full-year 2026 guidance was raised to approximately $1 billion in total global revenue (from $950 million) and $915–920 million in BRIUMVI U.S. net product revenue (from $890–905 million).
  • The company repurchased $100 million of common stock during the quarter, bringing total repurchases to $300 million, while cash and investments rose to $556.7 million as of September 30, 2026.
  • Future outlook includes anticipated top-line Phase 3 data for subcutaneous BRIUMVI by year-end 2026 or early 2027, with potential launches for simplified IV initiation in mid-2027 and subcutaneous BRIUMVI in 2028.
Company
TG THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology